Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119653 | 1.00 | KMT2A (0.55) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL119648 | 1.00 | KMT2A (0.55) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL12898821 | 1.00 | KMT2A (0.55) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL29400732 | 1.00 | KMT2A (0.55) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL178688 | 1.00 | KMT2A (0.55) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL25358347 | 0.97 | KMT2A (0.57) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL21462054 | 0.97 | KMT2A (0.57) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL29401249 | 0.97 | KMT2A (0.57) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL178771 | 0.97 | KMT2A (0.57) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL29350360 | 0.97 | KMT2A (0.57) | KMT2AMDM2TLR2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612428-B2 | Process for solid-phase peptide synthesis and device | KREUZER OLIVER JOHANNES (DE) | 2026-04-28 | — | — | US | disclosed |
| US-12569536-B2 | Macrocyclic peptides for targeted inhibition of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-3911661-B1 | ULTRASOUND ASSISTED PROCESS FOR SOLID-PHASE PEPTIDE SYNTHESIS AND DEVICE | KREUZER OLIVER JOHANNES (DE) | 2024-05-01 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| WO-2022197554-A1 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | UNIVERSITY OF MASSACHUSETTS (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-11353448-B2 | Methods and compositions for quantifying metabolites and proteins from single cells | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220096594-A1 | MACROCYCLIC PEPTIDES FOR TARGETED INHIBITION OF AUTOPHAGY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-31 | — | — | US | disclosed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | PALATIN TECHNOLOGIES INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | KMT2A 3958/4885MDM2 938/4885TLR2 4684/4885 |
| US-12569536-B2 | Macrocyclic peptides for targeted inhibition of autophagy | ATG7, SQSTM1, VIP | KMT2A 803/4885MDM2 943/4885TLR2 1741/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | KMT2A 4377/4885MDM2 4343/4885TLR2 502/4885 |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | KMT2A 4601/4885MDM2 4863/4885TLR2 874/4885 |
| US-12612428-B2 | Process for solid-phase peptide synthesis and device | MAX, SPATS2L, QPCTL | KMT2A 1439/4885MDM2 953/4885TLR2 2102/4885 |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | MC3R, GIPR, MC1R | KMT2A 4463/4885MDM2 3908/4885TLR2 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.